But there has been little visible impact so far on its pay policy, except that Sir PeterJob is stepping down as chairman of the group's remuneration committee on October 1st (he will remain a member).
Peter Dolan lost his job as Bristol's chief executive over the botched negotiation that allowed Canadian drugmaker Apotex to launch a generic version of Plavix at almost no financial risk.